Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 6, 2008

View Archived Issues

Addition of saxagliptin to a sulfonylurea or thiazolidinedione improves glucose control

Sucrose octasulphate demonstrates oral antirheumatic activity

Galectin-3 as potential therapeutic target in post-ischemic functional recovery

New treatment option for Wilson's disease disclosed in recent SSV patent

Novel treatments for endocrine-associated disorders imparted in recent patents

Recent GSK patent describes new analgesic agents

MediGene spins out mTCR technology platform to newly founded Immunocore

PharmAthene enters into strategic alliance with Panacea Biotec

OrthoLogic changes trade name to Capstone Therapeutics

Kringle files IND with FDA for phase I clinical trial of recombinant human HGF in renal disease

Affymetrix and MPI sign agreement for Affymetrix microarray technology in cancer

pSivida reports 6-month interim readout of the human PK Iluvien study

TorreyPines reports successful end-of-phase II meeting with FDA for tezampanel

Exelixis files IND with the FDA for XL-888

Ironwood raises USD 50 million for linaclotide phase III development program

Aeolus receives milestone payment from ARCA following acceptance of bucindolol NDA

PPD acquires InnoPharm

RegeneRx seeks strategic partner to develop RGN-457 for cystic fibrosis

Meda and Recordati sign long-term agreement for Lercadip in Spain

Mentor reports positive results from phase III clinical trial of PurTox in glabellar rhytides

Emergent signs new contract with HHS to supply anthrax vaccine BioThrax for SNS

Dara completes toxicology studies neeeded for phase I trials of DB-959, gives pipeline update

Daiichi Sankyo and Kuhnil initiate enrollment in phase II trial of nimotuzumab in gastric cancer

Kyowa Hakko Kogyo and Kirin Pharma complete business merger

Toctino receives marketing authorization in Germany

R&D highlights from the UBS Global Life Sciences Conference in New York: Enobia Pharma

Interim analysis of phase II sorafenib study shows safety and activity against thyroid cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...